Prelude Therapeutics Inc (PRLD)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue from license agreement | - | - | 3 | |
| Research and development | 25.784 | 28.816 | 29.457 | |
| General and administrative | 6.41 | 5.79 | 7.919 | |
| Total operating expenses | 32.194 | 34.606 | 37.376 | |
| Loss from operations | -32.194 | -34.606 | -34.376 | |
| Other income, net | 0.963 | 2.521 | 2.105 | |
| Net loss | -31.231 | -32.085 | -32.271 | |
| Unrealized loss on marketable securities, net of tax | -0.013 | -0.023 | 0.457 | |
| Comprehensive loss | -31.244 | -32.108 | -31.814 | |
| Earnings per share, basic, total | -0.41 | -0.42 | -0.43 | |
| Earnings per share, diluted, total | -0.41 | -0.42 | -0.43 | |
| Weighted average number of shares outstanding, basic, total | 75,993,941 | 75,986,281 | 75,855,949 | |
| Weighted average number of shares outstanding, diluted, total | 75,993,941 | 75,986,281 | 75,855,949 | |